[Form 4] ANI Pharmaceuticals, Inc. Insider Trading Activity

Rhea-AI Filing Summary

ANI Pharmaceuticals insider transaction: Thomas Rowland, SVP, Head - Established Brands, reported sale of 4,975 shares of ANI Pharmaceuticals, Inc. common stock on 08/12/2025 at a weighted average price of $85.71 per share. After the reported sale, the filing shows 40,794 shares beneficially owned.

The filing notes that 304 of those shares were acquired under the company's Employee Stock Purchase Plan and were exempt under Rule 16b-3. The Form 4 was submitted and signed by attorney-in-fact Meredith W. Cook on behalf of Thomas Rowland.

Positive

• Disclosure includes ESPP exemption: The filing explicitly notes 304 shares acquired under the Employee Stock Purchase Plan and exempt under Rule 16b-3.
• Complete transaction detail: The report provides sale date, weighted average sale price ($85.71), and post-transaction beneficial ownership (40,794 shares).

Negative

• Insider sale reported: Thomas Rowland sold 4,975 shares on 08/12/2025, which may reduce his direct stake.
• Sale price indicates realized disposition: Shares sold at a weighted average of $85.71, representing a cash exit of the reported lots.

Insights

Securities Analyst

TL;DR: Reporting officer sold 4,975 shares at a weighted average $85.71; remaining beneficial ownership shown as 40,794 shares.

The Form 4 discloses a routine open-market sale of 4,975 shares on 08/12/2025 with the weighted average sale price reported as $85.71. The filing quantifies post-transaction beneficial ownership at 40,794 shares and separately discloses 304 shares acquired under the Employee Stock Purchase Plan that were exempt under Rule 16b-3. This submission conveys transaction specifics required by Section 16 reporting rules and provides clear pricing and share count details for market analysis.

Corporate Governance Expert

TL;DR: Disclosure appears complete for the transaction; includes exemption note for ESPP shares and attorney-in-fact signature.

The Form 4 includes the transaction date, transaction code, number of shares sold, weighted average sale price, and resulting beneficial ownership, meeting standard disclosure elements. It also documents that 304 shares were acquired under the employee plan and treated as exempt under Rule 16b-3. The form bears an attorney-in-fact signature, indicating an authorized filing. No additional governance events or amendments are reported in this filing.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Rowland Thomas Andrew

(Last) (First) (Middle)

C/O ANI PHARMACEUTICALS, INC.

210 MAIN STREET WEST

(Street)

BAUDETTE MN 56623

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ANI PHARMACEUTICALS INC [ ANIP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, HEAD - ESTABLISHED BRANDS

3. Date of Earliest Transaction (Month/Day/Year)
08/12/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/12/2025		S		4,975(1)	D	$85.71	40,794(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The shares were sold in multiple trades at prices ranging from $85.52 to $86.22. The price reported above reflects the weighted average sales price.

2. Includes 304 shares of ANI Pharmaceuticals, Inc. Common Stock that were acquired under the ANI Pharmaceuticals, Inc. Employee Stock Purchase Plan in transactions that were exempt under Rule 16b-3(d) and Rule 16b-3(c).

Remarks:

	/s/ Thomas Rowland, by attorney-in-fact Meredith W. Cook	08/14/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Thomas Rowland sell according to the ANIP Form 4?

The Form 4 reports that Thomas Rowland sold 4,975 shares of ANI Pharmaceuticals common stock on 08/12/2025.

At what price were the ANIP shares sold in the Form 4 transaction?

The filing reports a weighted average sale price of $85.71 per share, with individual trades ranging from $85.52 to $86.22.

How many ANIP shares does the reporting person own after the transaction?

After the reported sale, the Form 4 shows beneficial ownership of 40,794 shares.

Were any shares acquired under an employee plan noted in the ANIP filing?

Yes. The filing states 304 shares were acquired under the ANI Pharmaceuticals Employee Stock Purchase Plan and were exempt under Rule 16b-3.

Who signed the ANIP Form 4 filing for Thomas Rowland?

The Form 4 is signed by attorney-in-fact Meredith W. Cook on behalf of Thomas Rowland.